Prostate Imaging Using MRI +/- Contrast Enhancement

Overview

About this study

This prospective clinical trial (PRostate Imaging using Mri +/- contrast Enhancement (PRIME)) aims to assess whether biparametric MRI (bpMRI) is non-inferior to multiparametric mpMRI (mpMRI) in the detection of clinically significant prostate cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Men at least 18 years of age referred with clinical suspicion of prostate cancer.
Serum PSA ≤ 20ng/ml.
Fit to undergo all procedures listed in protocol.
Able to provide written informed consent.

Exclusion Criteria:

Prior prostate biopsy.
Prior treatment for prostate cancer.
Prior prostate MRI on a previous encounter.
Contraindication to MRI.
Contraindication to prostate biopsy.
Unfit to undergo any procedures listed in protocol.

Eligibility last updated 10/5/21. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Lance Mynderse, M.D.	Closed for enrollment	Contact information: Kerry Peterson (507) 293-0168 Peterson.Kerry@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Lance Mynderse, M.D.

Closed for enrollment

Contact information:

Kerry Peterson

(507) 293-0168

Peterson.Kerry@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials